6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03462641
(ClinicalTrials.gov)
March 9, 20186/3/2018Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil ArmModulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil ArmParkinson DiseaseDrug: Flumazenil;Drug: PlaceboUniversity of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)Completed50 Years99 YearsAll26Phase 1/Phase 2United States
2NCT03440112
(ClinicalTrials.gov)
January 29, 201826/1/2018Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil ArmModulation of GABA-A Receptors and Axial Motor Impairments in ParkinsonParkinson DiseaseDrug: Clarithromycin (Not used as of 4/2020);Drug: Placebo (Not used as of 4/2020);Drug: Transdermal flumazenil (Added 4/2020);Drug: Placebo (Added 4/2020)Nicolaas Bohnen, MD, PhDNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting50 YearsN/AAll30Phase 1/Phase 2United States
3JPRN-UMIN000011111
2013/07/1615/07/2013Spinal blood flow and metabolism in neurological diseases motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophyPET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesNULLRecruiting20years-oldNot applicableMale and Female70Not applicableJapan